Smith D B, Scarffe J H, Wagstaff J, Johnston R J
Department of Medical Oncology, Charing Cross Hospital, London, England.
Cancer Treat Rep. 1987 Dec;71(12):1265-6.
Fourteen patients with malignant carcinoid tumors were treated with rDNA alfa 2b interferon by sc injection three times per week. Treatment was started at a dose of 2 milliunits/m2, with escalations to 3, 5, 7, and 10 milliunits/m2 at 2-week intervals depending on toxicity. No objective tumor regressions were seen, but five of 14 patients (36%) had 50% reduction in 24-hour 5-hydroxyindoleacetic acid excretion and six of nine (67%) with carcinoid syndrome had a good symptomatic response. Biochemical responses occurred during the first 8 weeks of treatment, and escalation of the dose of interferon did not increase the response rate. The rDNA alfa 2b interferon has activity in patients with the carcinoid syndrome and should be used at a low dose (2-3 milliunits/m2) until symptoms recur.
14例恶性类癌瘤患者接受了重组DNAα2b干扰素治疗，通过皮下注射，每周3次。治疗起始剂量为2百万单位/平方米，根据毒性情况，每2周剂量递增至3、5、7和10百万单位/平方米。未观察到客观肿瘤消退，但14例患者中有5例（36%）24小时5-羟吲哚乙酸排泄减少50%，9例类癌综合征患者中有6例（67%）有良好的症状反应。生化反应出现在治疗的前8周，且干扰素剂量递增并未提高反应率。重组DNAα2b干扰素对类癌综合征患者有活性，应采用低剂量（2 - 3百万单位/平方米）使用，直至症状复发。
